Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists

被引：455

作者：

Olefsky, JM ^{[1
]}

机构：

[1] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2000年 / 106卷 / 04期

关键词：

D O I：

10.1172/JCI10843

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

[No abstract available]

引用

页码：467 / 472

页数：6

共 49 条

[1] PPARγ is required for placental, cardiac, and adipose tissue development [J].

Barak, Y ;

Nelson, MC ;

Ong, ES ;

Jones, YZ ;

Ruiz-Lozano, P ;

Chien, KR ;

Koder, A ;

Evans, RM .

MOLECULAR CELL, 1999, 4 (04) :585-595

[2] Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension [J].

Barroso, I ;

Gurnell, M ;

Crowley, VEF ;

Agostini, M ;

Schwabe, JW ;

Soos, MA ;

Maslen, GL ;

Williams, TDM ;

Lewis, H ;

Schafer, AJ ;

Chatterjee, VKK ;

O'Rahilly, S .

NATURE, 1999, 402 (6764) :880-883

[3]

Berkowitz R, 1996, DIABETES, V45, P1572

[4] Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat [J].

Braissant, O ;

Foufelle, F ;

Scotto, C ;

Dauca, M ;

Wahli, W .

ENDOCRINOLOGY, 1996, 137 (01) :354-366

[5] Troglitazone action is independent of adipose tissue [J].

Burant, CF ;

Sreenan, S ;

Hirano, KI ;

Tai, TAC ;

Lohmiller, J ;

Lukens, J ;

Davidson, NO ;

Ross, S ;

Graves, RA .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11) :2900-2908

[6]

BURANT CF, 1999, DIABETES S1, V48, P44

[7] Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone [J].

Camp, HS ;

Li, O ;

Wise, SC ;

Hong, YH ;

Frankowski, CL ;

Shen, XQ ;

Vanbogelen, R ;

Leff, T .

DIABETES, 2000, 49 (04) :539-547

[8] INVITRO STUDIES ON THE ACTION OF CS-045, A NEW ANTIDIABETIC AGENT [J].

CIARALDI, TP ;

GILMORE, A ;

OLEFSKY, JM ;

GOLDBERG, M ;

HEIDENREICH, KA .

METABOLISM-CLINICAL AND EXPERIMENTAL, 1990, 39 (10) :1056-1062

[9] A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity [J].

Deeb, SS ;

Fajas, L ;

Nemoto, M ;

Pihlajamäki, J ;

Mykkänen, L ;

Kuusisto, J ;

Laakso, M ;

Fujimoto, W ;

Auwerx, J .

NATURE GENETICS, 1998, 20 (03) :284-287

[10] Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome [J].

Ehrmann, DA ;

Schneider, DJ ;

Sobel, BE ;

Cavaghan, MK ;

Imperial, J ;

Rosenfield, RL ;

Polonsky, KS .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (07) :2108-2116

← 1 2 3 4 5 →